scholarly journals The role of biomarker in pancreatic neuroendocrine tumor

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Xiaofan Guo ◽  
Song Gao ◽  
Zekun Li ◽  
Jihui Hao
2015 ◽  
Vol 110 ◽  
pp. S86-S87
Author(s):  
Siddharth B. Javia ◽  
Dishita Pandya ◽  
Asha Kuruvilla ◽  
Erik Rahimi ◽  
Jennifer Lamberth ◽  
...  

Gland Surgery ◽  
2018 ◽  
Vol 7 (1) ◽  
pp. 36-41 ◽  
Author(s):  
Kai Pun Wong ◽  
Julian Shun Tsang ◽  
Brian Hung-Hin Lang

Author(s):  
Mirella Hage ◽  
Ségolène Hescot ◽  
Amani Asnacios ◽  
Sophia Bakopoulou ◽  
Laure Cazabat ◽  
...  

Genes ◽  
2021 ◽  
Vol 12 (4) ◽  
pp. 512
Author(s):  
Aleksandra Gilis-Januszewska ◽  
Anna Bogusławska ◽  
Kornelia Hasse-Lazar ◽  
Beata Jurecka-Lubieniecka ◽  
Barbara Jarząb ◽  
...  

Multiple neuroendocrine neoplasia type 1 (MEN1) is a rare genetic disorder with an autosomal dominant inheritance, predisposing carriers to benign and malignant tumors. The phenotype of MEN1 syndrome varies between patients in terms of tumor localization, age of onset, and clinical aggressiveness, even between affected members within the same family. We describe a heterogenic phenotype of the MEN1 variant c.781C>T (LRG_509t1), which was previously reported only once in a family with isolated hyperparathyroidism. A heterozygous missense variant in exon 4 of the gene was identified in the sequence of the MEN1 gene, i.e., c.781C>T, leading to the amino acid change p.Leu261Phe in a three-generation family. In the screened family, 5/6 affected members had already developed hyperparathyroidism. In the index patient and two other family members, an aggressive course of pancreatic neuroendocrine tumor (insulinoma and non-functioning neuroendocrine tumors) with dissemination was diagnosed. In the index patient, late diagnosis and slow progression of the disseminated neuroendocrine tumor have been observed (24 years of follow-up). The very rare variant of MEN1, LRG_509t1 c.781C>T /p.Leu261Phe (LRG_509p1), diagnosed within a three-generation family has a heterogenic clinical presentation. Further follow-up of the family members should be carried out to confirm the spectrum and exact time of clinical presentation.


Sign in / Sign up

Export Citation Format

Share Document